华厦眼科医院集团股份有限公司 2025 年半年度报告全文 华厦眼科医院集团股份有限公司 2025 年半年度报告 2025 年 8 月 1 华厦眼科医院集团股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人苏庆灿、主管会计工作负责人陈凤国及会计机构负责人(会计 主管人员)陈鹭燕声明：保证本半年度报告中财务报告的真实、准确、完整。 除下列董事外，其他董事亲自出席了审议本次半年报的董事会会议： | 未亲自出席董事姓名 | 未亲自出席董事职务 | 未亲自出席会议原因 | 被委托人姓名 | | --- | --- | --- | --- | | 苏庆灿 | 董事长 | 因个人原因 | 陈凤国 | 本报告涉及未来发展规划和经营计划等前瞻性描述不构成公司对投资者的 实质承诺，投资者及相关人士均应当对此保持足够的风险认识，并且应当理 解规划、计划、预测与承诺之间的差异。敬请投资者注意投资风险。 报告期内，公司主营业务、核心竞争力、主要财务指 ...

Company Overview - Huaxia Eye Hospital Group Co., Ltd. specializes in ophthalmology services, with key offerings including cataract projects, posterior segment projects, refractive projects, and comprehensive optometry projects [1] - As of the first quarter of 2025, the company reported revenue of 1.093 billion yuan, representing a year-on-year increase of 11.74%, while net profit was 150 million yuan, showing a year-on-year decrease of 4.00% [1] Financial Metrics - The company's closing stock price on August 15 was 20.67 yuan, with a PE ratio of 41.11 times and a total market capitalization of 17.363 billion yuan [1] - The average PE ratio for the healthcare services industry is 49.76 times, with a median of 64.18 times, placing Huaxia Eye Hospital at the 26th position within the industry [1][2] - The company has a sales gross margin of 44.97% as per the latest financial report [1] Institutional Holdings - As of the first quarter of 2025, five institutions hold shares in Huaxia Eye Hospital, all being funds, with a total holding of 3.5318 million shares valued at 6.8 million yuan [1]

Group 1 - The core viewpoint of the articles highlights Huaxia Eye Hospital's stock performance, with a closing price of 20.91 yuan, an increase of 2.35%, and a rolling PE ratio of 41.58, marking a new low in 97 days, with a total market value of 17.564 billion yuan [1] - The average PE ratio for the medical services industry is 48.03, with a median of 60.62, placing Huaxia Eye Hospital at the 26th position within the industry [1] - On August 11, Huaxia Eye Hospital experienced a net inflow of main funds amounting to 8.5187 million yuan, with a total inflow of 7.3312 million yuan over the past five days [1] Group 2 - Huaxia Eye Hospital's main business focuses on specialized ophthalmic medical services, with key products including cataract projects, posterior segment projects, refractive projects, and comprehensive optometry projects [1] - The latest quarterly report for Q1 2025 shows that the company achieved an operating income of 1.093 billion yuan, a year-on-year increase of 11.74%, and a net profit of 150 million yuan, reflecting a year-on-year decrease of 4.00%, with a gross profit margin of 44.97% [1] - The PE ratio (TTM) for Huaxia Eye Hospital is 41.58, while the industry average is 48.03, and the industry median is 60.62 [2]

Summary of Key Points Core Viewpoint - The 2024 A-share Secretary Data Report indicates that the total salary of A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 754,300 yuan, highlighting the significant role of secretaries in connecting investors and listed companies [1][2]. Group 1: Overall Salary and Demographics - The total salary for A-share listed company secretaries in 2024 is 4.086 billion yuan, with an average annual salary of 754,300 yuan [1]. - Among the secretaries, those aged 40 and below constitute 43% of the market, while those aged 50 and above account for 22% [1]. - The educational background of secretaries shows that 34% hold a bachelor's degree, 52% have a master's degree, and 14% possess a doctoral degree [1]. Group 2: Industry-Specific Salary Insights - The average annual salary for secretaries in the pharmaceutical and medical service sector is 839,200 yuan [2]. - The distribution of salaries shows that 24% earn below 500,000 yuan, 48% earn between 500,000 and 1 million yuan, and 28% earn above 1 million yuan [2]. - The top three highest-paid secretaries are Gilbert Shing Chung Li from Kanglong Chemical with 1.9855 million yuan, Gao Dapeng from Zhaoyan New Drug with 1.7384 million yuan, and Xu Xiangke from Kailaiying with 1.6114 million yuan [2].

Core Insights - The report highlights that in 2024, the total salary of A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earned over 1 million yuan, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for company secretaries in the medical and healthcare services sector is 839,200 yuan [2] - The distribution of salaries shows that 24% earn below 500,000 yuan, 48% earn between 500,000 and 1 million yuan, and 28% earn above 1 million yuan [2] - The top three highest-paid company secretaries are Gilbert Shing Chung Li from Kanglong Chemical with 1.9855 million yuan, Gao Dapeng from Zhaoyan New Drug with 1.7384 million yuan, and Xu Xiangke from Kailaiying with 1.6114 million yuan [2] Age and Education Distribution - Company secretaries aged 40 and below constitute 43% of the market, while those aged 50 and above account for 22% [1] - The educational background of company secretaries shows that 34% hold a bachelor's degree, 52% have a master's degree, and 14% possess a doctoral degree [1] - Among the doctoral degree holders, there are 7 individuals, with the only full-time doctoral company secretary in the industry being Cao Nai'en from Huaxia Eye Hospital [1]

Core Viewpoint - Huaxia Eye Hospital's stock closed at 20.53 yuan, up 3.01%, with a rolling PE ratio of 40.83, marking a new low in 80 days, and a total market value of 17.245 billion yuan [1] Group 1: Company Performance - For Q1 2025, the company reported revenue of 1.093 billion yuan, a year-on-year increase of 11.74%, and a net profit of 150 million yuan, reflecting a year-on-year decrease of 4.00% [1] - The company's gross profit margin stands at 44.97% [1] Group 2: Shareholder Information - As of March 31, 2025, the number of shareholders reached 20,981, an increase of 1,961 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 3: Industry Comparison - The average PE ratio for the medical services industry is 46.96, with a median of 54.55, placing Huaxia Eye Hospital at the 24th position within the industry [1] - The static PE ratio for Huaxia Eye Hospital is 40.23, and the price-to-book ratio is 2.92 [2]

Core Insights - The vision correction industry in China is experiencing rapid growth driven by policy support, market demand, and technological innovation [1][5][22] - The market size is projected to reach 215 billion yuan in 2024, with a year-on-year growth of 11.6% [1][14] - The industry has established a comprehensive treatment system combining surgical and optical correction methods [1][10] Policy Support - The Chinese government has implemented a series of policies to enhance eye health, including the "Comprehensive Prevention and Control of Myopia in Children and Adolescents Implementation Plan" [5][7] - Policies aim to create a management system covering prevention, treatment, and rehabilitation, promoting standardized and high-quality development in the industry [5][22] Market Demand - The number of myopic individuals in China has surpassed 600 million, with a significant increase in myopia rates across all age groups [8][12] - The myopia rate among high school students exceeds 80%, and projections suggest that the rate for the 16-24 age group may reach 94% [8][12] - This growing patient base provides a continuous driving force for the industry's development [1][8] Industry Structure - The vision correction industry has formed a complete industrial chain, with upstream focusing on optical materials and high-end equipment, while midstream includes the production of glasses and surgical devices [10][20] - The downstream market is served by medical institutions, optical centers, and e-commerce platforms, with private eye hospitals contributing over 60% of refractive surgeries [10][12] Competitive Landscape - The industry features a multi-layered competitive structure, with foreign brands dominating high-end markets while domestic brands accelerate their presence [20][21] - Key players include Aier Eye Hospital, Aibo Medical, and Opcon Vision, each with distinct market positions and strategies [21][20] Future Trends - The industry is expected to continue expanding due to policy-driven demand and technological advancements, with a focus on full-cycle management of eye health [22][24] - Innovations such as AI-assisted surgeries and domestic alternatives to imported products are reshaping the competitive landscape [24][25] - The trend towards service accessibility is being driven by private institutions expanding into lower-tier cities and the growth of online sales channels [25][22]

Market Overview - The Shanghai Composite Index closed at 3519.65 points, above the annual line, with a change of 0.27% [1] - The total trading volume of A-shares reached 14809.22 billion yuan [1] Stocks Breaking Annual Line - A total of 46 A-shares have surpassed the annual line today, with notable stocks including: - Siyuan Electric (002028) with a deviation rate of 7.62% - Huaming Equipment (002270) with a deviation rate of 2.75% - Tongyi Co., Ltd. (300538) with a deviation rate of 2.63% [1] Deviation Rate Rankings - The top stocks with the highest deviation rates from the annual line include: - Siyuan Electric: 10.00% increase, latest price 76.99 yuan, deviation rate 7.62% - Huaming Equipment: 3.25% increase, latest price 16.85 yuan, deviation rate 2.75% - Tongyi Co., Ltd.: 2.63% increase, latest price 16.02 yuan, deviation rate 2.63% [1] Additional Stocks with Minor Deviations - Stocks with smaller deviation rates that have just crossed the annual line include: - Daqin Railway and *ST Haiyuan with minimal deviation rates [1]

证券代码：301267 证券简称：华厦眼科 公告编号：2025-021 华厦眼科医院集团股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指 引第 9 号——回购股份》等相关规定，华厦眼科医院集团股份有限公司（以下简 称"公司"或"本公司"）回购专用账户中的股份不参与本次权益分派。公司 2024 年年度权益分派以当前总股本 840,000,000 股剔除已回购股份 7,527,840 股 后的 832,472,160 股为基数，向全体股东每 10 股派发现金红利人民币 2.20 元（含 税），合计派发现金红利 183,143,875.20 元。 2、本次权益分派实施后计算除权除息价格时，以公司总股本（含回购股份， 即 840,000,000 股）折算后的每 10 股现金红利（含税）=现金分红总额/总股本（含 回购股份）*10=183,143,875.20 元/840,000,000 股*10=2.180284 元（保留六位小 数，最后一位直 ...

Core Viewpoint - Huaxia Eye Hospital Group, in collaboration with Shanghai University, Nova Coffee, and Shanghai Xin'ao Guangming Public Welfare Foundation, launched the "Eye Health Dry Eye Moisturizing Public Welfare Activity and Technology Innovation Platform Release Ceremony," introducing the first AI self-test tool for dry eye in China, named "Smart Eye Guardian" [1][2]. Group 1: AI Self-Test Tool - The "Smart Eye Guardian" mini-program is the first AI self-test tool for dry eye in China, allowing users to upload images and videos for quick, contactless preliminary diagnosis of dry eye symptoms [2][3]. - The program aims to address the increasing prevalence of dry eye, which affects approximately 360 million people in China, growing at a rate of 10% annually [3]. Group 2: Public Health Challenge - The World Health Organization reports that over 2 billion people globally spend more than 8 hours a day on screens, with about 35% experiencing dry eye symptoms [3]. - The rise of digital device usage has led to a significant increase in dry eye cases, highlighting the need for innovative solutions like the "Smart Eye Guardian" [3]. Group 3: Collaborative Initiatives - Huaxia Eye Hospital partnered with Nova Coffee to launch the "Good for Eyes" blueberry beverage, targeting the 20-45 age group, which faces higher risks of dry eye due to busy lifestyles and lack of awareness [4]. - The collaboration includes a public welfare project where 0.1 yuan from each "nourishing coffee" sold will be donated to a public welfare fund, promoting a "consumption equals public welfare" model [4]. Group 4: Community Engagement - Over 50 hospitals under Huaxia Eye Hospital will participate in eye health public welfare projects, conducting a series of dry eye care activities in the coming month [4]. - The initiative aims to fill the gap in dry eye health education and patient care, focusing on preventive measures and raising awareness among high screen-time populations [4]. Group 5: Professional Insights - Experts emphasized the importance of understanding the causes and development of dry eye, advocating for good lifestyle habits to prevent the condition [5]. - The misconception that dry eye is untreatable was addressed, with experts stating that all cases can be effectively treated once the underlying causes are identified [5].